These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

496 related items for PubMed ID: 19538866

  • 1. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP, Liu BR, Shi MQ, Liu XZ, Hu WJ, Zou ZY, Wei J.
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
    [Abstract] [Full Text] [Related]

  • 2. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H.
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [Abstract] [Full Text] [Related]

  • 3. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Zhou C, Ren S, Zhou S, Zhang L, Su C, Zhang Z, Deng Q, Zhang J.
    Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
    [Abstract] [Full Text] [Related]

  • 4. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
    Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Viñolas N, Paz-Ares L, Lopez-Vivanco G, Muñoz MA, Felip E, Alberola V, Camps C, Domine M, Sanchez JJ, Sanchez-Ronco M, Danenberg K, Taron M, Gandara D, Rosell R.
    J Clin Oncol; 2007 Jul 01; 25(19):2747-54. PubMed ID: 17602080
    [Abstract] [Full Text] [Related]

  • 5. [ERCC1 expression and outcomes of neo-adjuvant chemotherapy in elderly patients with non-small cell lung cancer].
    Li GF, Deng SJ, Weng WW, Guo G, Chen N.
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Sep 01; 30(9):2131-3. PubMed ID: 20855270
    [Abstract] [Full Text] [Related]

  • 6. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
    Booton R, Ward T, Ashcroft L, Morris J, Heighway J, Thatcher N.
    J Thorac Oncol; 2007 Oct 01; 2(10):902-6. PubMed ID: 17909351
    [Abstract] [Full Text] [Related]

  • 7. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
    Hwang IG, Ahn MJ, Park BB, Ahn YC, Han J, Lee S, Kim J, Shim YM, Ahn JS, Park K.
    Cancer; 2008 Sep 15; 113(6):1379-86. PubMed ID: 18623378
    [Abstract] [Full Text] [Related]

  • 8. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY, Liang XM, Lin SX, Luo RZ, Hou JH, Zhang L.
    Ai Zheng; 2004 Jul 15; 23(7):845-50. PubMed ID: 15248926
    [Abstract] [Full Text] [Related]

  • 9. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
    Olaussen KA, Mountzios G, Soria JC.
    Curr Opin Pulm Med; 2007 Jul 15; 13(4):284-9. PubMed ID: 17534174
    [Abstract] [Full Text] [Related]

  • 10. Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy.
    Vassalou H, Stathopoulos E, Fiolitaki G, Koutsopoulos A, Voutsina A, Georgoulias V, Mavroudis D.
    Lung Cancer; 2013 Nov 15; 82(2):324-9. PubMed ID: 23993732
    [Abstract] [Full Text] [Related]

  • 11. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A, Sørensen JB.
    Lung Cancer; 2009 May 15; 64(2):131-9. PubMed ID: 18804893
    [Abstract] [Full Text] [Related]

  • 12. [Expression of ERCC1 mRNA and its impact on the prognosis of patients with non-small cell lung cancer].
    Ma W, Li W, Gao M, Li XN.
    Zhonghua Zhong Liu Za Zhi; 2011 May 15; 33(5):371-4. PubMed ID: 21875468
    [Abstract] [Full Text] [Related]

  • 13. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Su L, Christiani DC.
    Clin Cancer Res; 2004 Aug 01; 10(15):4939-43. PubMed ID: 15297394
    [Abstract] [Full Text] [Related]

  • 14. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
    Li Z, Qing Y, Guan W, Li M, Peng Y, Zhang S, Xiong Y, Wang D.
    Cancer Chemother Pharmacol; 2014 Oct 01; 74(4):777-86. PubMed ID: 25107571
    [Abstract] [Full Text] [Related]

  • 15. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
    Azuma K, Sasada T, Kawahara A, Hattori S, Kinoshita T, Takamori S, Ichiki M, Imamura Y, Ikeda J, Kage M, Kuwano M, Aizawa H.
    Cancer Chemother Pharmacol; 2009 Aug 01; 64(3):565-73. PubMed ID: 19123003
    [Abstract] [Full Text] [Related]

  • 16. Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2.
    Ko JC, Su YJ, Lin ST, Jhan JY, Ciou SC, Cheng CM, Chiu YF, Kuo YH, Tsai MS, Lin YW.
    Lung Cancer; 2010 Aug 01; 69(2):155-64. PubMed ID: 19962780
    [Abstract] [Full Text] [Related]

  • 17. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F, Sun X, Sun N, Qin S, Cheng H, Feng J, Chen B, Cheng L, Lu Z, Ji J, Zhou Y.
    Am J Clin Oncol; 2010 Oct 01; 33(5):489-94. PubMed ID: 20351547
    [Abstract] [Full Text] [Related]

  • 18. Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC.
    Friboulet L, Barrios-Gonzales D, Commo F, Olaussen KA, Vagner S, Adam J, Goubar A, Dorvault N, Lazar V, Job B, Besse B, Validire P, Girard P, Lacroix L, Hasmats J, Dufour F, André F, Soria JC.
    Clin Cancer Res; 2011 Sep 01; 17(17):5562-72. PubMed ID: 21750204
    [Abstract] [Full Text] [Related]

  • 19. ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy.
    Das M, Riess JW, Frankel P, Schwartz E, Bennis R, Hsieh HB, Liu X, Ly JC, Zhou L, Nieva JJ, Wakelee HA, Bruce RH.
    Lung Cancer; 2012 Aug 01; 77(2):421-6. PubMed ID: 22555222
    [Abstract] [Full Text] [Related]

  • 20. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.
    Simon G, Sharma A, Li X, Hazelton T, Walsh F, Williams C, Chiappori A, Haura E, Tanvetyanon T, Antonia S, Cantor A, Bepler G.
    J Clin Oncol; 2007 Jul 01; 25(19):2741-6. PubMed ID: 17602079
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.